Key result
Patients with type 2 diabetes mellitus had significantly higher median serum betatrophin levels compared to normal controls (54.815 ng/l vs 11.250 ng/l; P<0.001).
Why the study?
Betatrophin is induced by insulin resistance and reported to modulate β-cell mass and glucose homeostasis, prompting evaluation of its role in patients with type 2 diabetes mellitus.
Are serum betatrophin levels higher in patients with type 2 diabetes mellitus compared to healthy controls?
Population
80 subjects, including 40 patients with type 2 diabetes mellitus and 40 matched controls
Comparison
Type 2 diabetes mellitus patients vs age- and sex-matched normal controls
Design
Clinical study
Authors
Loading...
Association with type 2 diabetes is hypothesis-generating; leaves open biomarker or therapeutic potential pending prospective validation.
Case-Control (n=80)
No
Are serum betatrophin levels higher in patients with type 2 diabetes mellitus compared to healthy controls?
Absolute Event Rate: 54.815% vs 11.25%
p-value: p=< 0.001
Serum betatrophin levels are significantly elevated in patients with type 2 diabetes mellitus, indicating a potential role in glucose homeostasis and insulin sensitivity.
El-Ghandour et al. (2019) conducted a case-control in Type 2 diabetes mellitus (n=80). Type 2 diabetes mellitus vs. Normal subjects was evaluated on Serum betatrophin level (ng/l) (p=< 0.001). Patients with type 2 diabetes mellitus had significantly higher median serum betatrophin levels compared to normal controls (54.815 ng/l vs 11.250 ng/l; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: